Gregory Grabowski to Male
This is a "connection" page, showing publications Gregory Grabowski has written about Male.
Connection Strength
0.353
-
More Than One-third of Orthopaedic Applicants Are in the Top 10%: The Standardized Letter of Recommendation and Evaluation of Orthopaedic Resident Applicants. Clin Orthop Relat Res. 2021 08 01; 479(8):1703-1708.
Score: 0.041
-
Epidural Abscess Caused by Gas-Producing Clostridium Septicum: A Case Report. JBJS Case Connect. 2019 Dec; 9(4):e0282.
Score: 0.037
-
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017 03 02; 543(7643):108-112.
Score: 0.030
-
CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11 years of therapy: clinical, histopathologic, and biochemical findings. Mol Genet Metab. 2015 Feb; 114(2):233-241.
Score: 0.025
-
Reversal of advanced disease in lysosomal acid lipase deficient mice: a model for lysosomal acid lipase deficiency disease. Mol Genet Metab. 2014 Jul; 112(3):229-41.
Score: 0.025
-
Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model. Mol Genet Metab. 2014 Feb; 111(2):163-71.
Score: 0.024
-
Tissue-specific effects of saposin A and saposin B on glycosphingolipid degradation in mutant mice. Hum Mol Genet. 2013 Jun 15; 22(12):2435-50.
Score: 0.023
-
Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012; 2012:13-8.
Score: 0.021
-
Esophageal and vertebral artery injuries during complex cervical spine surgery--avoidance and management. Orthop Clin North Am. 2012 Jan; 43(1):63-74, viii.
Score: 0.021
-
Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet. 2010 Feb 15; 19(4):634-47.
Score: 0.018
-
Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice. Hum Mol Genet. 2008 Aug 01; 17(15):2345-56.
Score: 0.016
-
Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels. Mol Genet Metab. 2008 Jun; 94(2):190-203.
Score: 0.016
-
Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model. J Lipid Res. 2006 Oct; 47(10):2161-70.
Score: 0.014
-
Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease. EBioMedicine. 2020 May; 55:102735.
Score: 0.009
-
A Prospective Multicenter Evaluation of the Value of the On-Call Orthopedic Resident. J Grad Med Educ. 2018 Feb; 10(1):91-94.
Score: 0.008
-
Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PLoS One. 2016; 11(9):e0162367.
Score: 0.007
-
Association Between Progranulin and Gaucher Disease. EBioMedicine. 2016 Sep; 11:127-137.
Score: 0.007
-
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis. 2010 Jun; 33(3):281-9.
Score: 0.005
-
Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood. 2009 Oct 08; 114(15):3181-90.
Score: 0.004